Compare NCA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCA | ACIU |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.3M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | NCA | ACIU |
|---|---|---|
| Price | $9.38 | $3.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 59.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.77 | $1.43 |
| 52 Week High | $9.12 | $4.00 |
| Indicator | NCA | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 72.60 | 64.73 |
| Support Level | $8.88 | $3.09 |
| Resistance Level | $8.92 | $3.73 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 94.12 | 91.86 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.